PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24646773-0 2014 Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months. Chromium 23-25 C-C motif chemokine ligand 2 Homo sapiens 17-21 31389404-7 2019 RESULTS: CCL2:Cr was significant independent predictor of BK virus nephropathy (OR 1.1 95% CI 1.0-1.2; p=0.04). Chromium 14-16 C-C motif chemokine ligand 2 Homo sapiens 9-13 31389404-9 2019 CONCLUSIONS: CCL2:Cr and CXCL10:Cr may seem to predict BK virus nephropathy. Chromium 18-20 C-C motif chemokine ligand 2 Homo sapiens 13-17 27548845-6 2016 RESULTS: Fifty-two patients (52/185, 28%) reached the primary outcome at a median 6.0 years, and their urinary CCL2:Cr was significantly higher compared with patients with stable allograft function (median [interquartile range], 38.6 ng/mmol [19.7-72.5] vs 25.9 ng/mmol [16.1-45.8], P = 0.009). Chromium 116-118 C-C motif chemokine ligand 2 Homo sapiens 111-115 27548845-7 2016 Low urinary CCL2:Cr (<=70.0 ng/mmol) was associated with 88% 5-year event-free survival compared with 50% with high urinary CCL2:Cr (P < 0.0001). Chromium 17-19 C-C motif chemokine ligand 2 Homo sapiens 12-16 27548845-8 2016 In a multivariate Cox-regression model, the only independent predictors of the primary outcome were high CCL2:Cr (hazard ratio [HR], 2.86; 95% confidence interval [95% CI], 1.33-5.73) and CXCL10:Cr (HR, 2.35; 95% CI, 1.23-4.88; both P = 0.009). Chromium 110-112 C-C motif chemokine ligand 2 Homo sapiens 105-109 27548845-9 2016 Urinary CCL2:Cr/CXCL10:Cr area under the curves were 0.62 (P = 0.001)/0.63 (P = 0.03), respectively. Chromium 13-15 C-C motif chemokine ligand 2 Homo sapiens 8-12 27548845-11 2016 CONCLUSIONS: This study confirms that urinary CCL2:Cr is an independent predictor of long-term allograft outcomes. Chromium 51-53 C-C motif chemokine ligand 2 Homo sapiens 46-50 27548845-12 2016 Urinary CCL2:Cr/CXCL10:Cr alone have similar prognostic performance, but when both are elevated, this suggests a worse prognosis. Chromium 13-15 C-C motif chemokine ligand 2 Homo sapiens 8-12 25324951-10 2014 CONCLUSIONS: The urinary MCP-1/Cr ratio is significantly elevated in neonates with severe obstruction requiring surgical intervention. Chromium 31-33 C-C motif chemokine ligand 2 Homo sapiens 25-30 24646773-1 2014 BACKGROUND: We have demonstrated that 6-month urinary CCL2: Cr is a predictor of interstitial fibrosis and tubular atrophy (IFTA) on 24-month biopsy and death-censored graft loss. Chromium 60-62 C-C motif chemokine ligand 2 Homo sapiens 54-58 24646773-3 2014 As early CCL2: Cr predicts late graft loss, the goal of this study was to determine if 6-month urinary CCL2: Cr was a predictor of IF+i at 24 months. Chromium 109-111 C-C motif chemokine ligand 2 Homo sapiens 103-107 24646773-5 2014 RESULTS: Six-month urinary CCL2: Cr was significantly higher in IF+i and transplant glomerulopathy patients compared with normal histology at 24 months. Chromium 33-35 C-C motif chemokine ligand 2 Homo sapiens 27-31 24646773-6 2014 By multivariate analysis, 6-month urinary CCL2: Cr was independently correlated with IF+i at 24 months (OR 2.78, 95% CI 1.38-6.12, AUC 0.695, P=0.003). Chromium 48-50 C-C motif chemokine ligand 2 Homo sapiens 42-46 24646773-7 2014 Six-month urinary CCL2: Cr was also an independent correlate of 6-month IF+i (OR 1.99, 95% CI 1.03-4.18, AUC 0.63, P=0.04). Chromium 24-26 C-C motif chemokine ligand 2 Homo sapiens 18-22 24646773-8 2014 Six-month urinary CCL2: Cr distinguished noninflamed renal tissue (normal, fibrosis) from IF+i with a sensitivity/specificity of 0.71/0.62 at a cutoff of 15 ng CCL2/mmol Cr (AUC 0.695, P=0.003, n=91). Chromium 24-26 C-C motif chemokine ligand 2 Homo sapiens 18-22 24646773-8 2014 Six-month urinary CCL2: Cr distinguished noninflamed renal tissue (normal, fibrosis) from IF+i with a sensitivity/specificity of 0.71/0.62 at a cutoff of 15 ng CCL2/mmol Cr (AUC 0.695, P=0.003, n=91). Chromium 170-172 C-C motif chemokine ligand 2 Homo sapiens 18-22 24646773-9 2014 CONCLUSIONS: Urinary CCL2: Cr may be useful for the noninvasive identification of patients with or at risk for IF+i. Chromium 27-29 C-C motif chemokine ligand 2 Homo sapiens 21-25 24646773-11 2014 Furthermore, urinary CCL2: Cr may also identify individuals who may benefit from novel interventional trials targeting IF+i. Chromium 27-29 C-C motif chemokine ligand 2 Homo sapiens 21-25 21130860-10 2011 CR extract alone inhibited monocyte chemoattractant protein (MCP)-1 release and in the presence of LPS, inhibited IL-10, TNF-alpha and MCP-1 release compared to LPS alone. Chromium 0-2 C-C motif chemokine ligand 2 Homo sapiens 27-67 21130860-10 2011 CR extract alone inhibited monocyte chemoattractant protein (MCP)-1 release and in the presence of LPS, inhibited IL-10, TNF-alpha and MCP-1 release compared to LPS alone. Chromium 0-2 C-C motif chemokine ligand 2 Homo sapiens 135-140 8671975-11 1996 In the normal control group, urinary MCP-1 levels ranged between 38 ng/mmol Cr and 74 ng/mmol Cr with a median of 50 ng/mmol Cr. Chromium 76-78 C-C motif chemokine ligand 2 Homo sapiens 37-42 8671975-11 1996 In the normal control group, urinary MCP-1 levels ranged between 38 ng/mmol Cr and 74 ng/mmol Cr with a median of 50 ng/mmol Cr. Chromium 94-96 C-C motif chemokine ligand 2 Homo sapiens 37-42 8671975-11 1996 In the normal control group, urinary MCP-1 levels ranged between 38 ng/mmol Cr and 74 ng/mmol Cr with a median of 50 ng/mmol Cr. Chromium 94-96 C-C motif chemokine ligand 2 Homo sapiens 37-42 23192155-0 2013 Increased urinary CCL2: Cr ratio at 6 months is associated with late renal allograft loss. Chromium 24-26 C-C motif chemokine ligand 2 Homo sapiens 18-22 23192155-7 2013 RESULTS: Urine CCL2: Cr at 6 months was significantly associated with death-censored graft loss (HR, 2.42; 95% CI, 1.54-3.82, P<0.0001). Chromium 21-23 C-C motif chemokine ligand 2 Homo sapiens 15-19 23192155-8 2013 On multivariate analysis, urinary CCL2: Cr at 6 months remained an independent predictor of death-censored graft loss (HR, 2.20; 95% CI, 1.18-4.10, P=0.01) after adjustment for pretransplant/de novo donor-specific antibody and delayed graft function. Chromium 40-42 C-C motif chemokine ligand 2 Homo sapiens 34-38 21348878-4 2011 Accordingly, this review examines how varying degrees of CR-induced weight loss (i.e., >10%, 5-10%, and <5% from baseline) impact plasma levels and expression of adiponectin, leptin, resistin, interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), and retinol-binding protein 4 (RBP-4). Chromium 57-59 C-C motif chemokine ligand 2 Homo sapiens 243-273 21348878-4 2011 Accordingly, this review examines how varying degrees of CR-induced weight loss (i.e., >10%, 5-10%, and <5% from baseline) impact plasma levels and expression of adiponectin, leptin, resistin, interleukin 6 (IL-6), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), and retinol-binding protein 4 (RBP-4). Chromium 57-59 C-C motif chemokine ligand 2 Homo sapiens 275-280 8671975-9 1996 RESULTS: Urinary excretion of MCP-1 in the Rj group ranged between 250 ng/mmol Cr and 3148 ng/mmol Cr with a median of 612 ng/mmol Cr. Chromium 79-81 C-C motif chemokine ligand 2 Homo sapiens 30-35 8671975-9 1996 RESULTS: Urinary excretion of MCP-1 in the Rj group ranged between 250 ng/mmol Cr and 3148 ng/mmol Cr with a median of 612 ng/mmol Cr. Chromium 99-101 C-C motif chemokine ligand 2 Homo sapiens 30-35 8671975-9 1996 RESULTS: Urinary excretion of MCP-1 in the Rj group ranged between 250 ng/mmol Cr and 3148 ng/mmol Cr with a median of 612 ng/mmol Cr. Chromium 99-101 C-C motif chemokine ligand 2 Homo sapiens 30-35 35363774-8 2022 Moreover, CDH2 and MCP-1 mRNAs inversely correlated with creatinine (r = -0.370 and r = -0.361, p<0.001) and Alb/Cr ratio (r = -0.355 and r = -0.297, p<0.001). Chromium 113-115 C-C motif chemokine ligand 2 Homo sapiens 19-24